Penumbra, Inc. (NYSE:PEN) insider Arani Bose sold 8,133 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $103.50, for a total transaction of $841,765.50. Following the sale, the insider now directly owns 700,815 shares of the company’s stock, valued at approximately $72,534,352.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Arani Bose also recently made the following trade(s):

  • On Monday, November 20th, Arani Bose sold 47,136 shares of Penumbra stock. The stock was sold at an average price of $105.15, for a total transaction of $4,956,350.40.
  • On Wednesday, November 15th, Arani Bose sold 16,452 shares of Penumbra stock. The stock was sold at an average price of $105.89, for a total transaction of $1,742,102.28.

Penumbra, Inc. (NYSE:PEN) opened at $107.55 on Wednesday. Penumbra, Inc. has a 52-week low of $57.85 and a 52-week high of $116.35.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. Penumbra’s quarterly revenue was up 24.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) earnings per share. analysts predict that Penumbra, Inc. will post -0.15 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Arani Bose Sells 8,133 Shares of Penumbra, Inc. (PEN) Stock” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/arani-bose-sells-8133-shares-of-penumbra-inc-pen-stock/1719081.html.

A number of analysts have recently commented on the stock. BMO Capital Markets reissued a “buy” rating and set a $96.00 target price on shares of Penumbra in a research note on Friday, October 13th. Canaccord Genuity boosted their price target on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Zacks Investment Research lowered shares of Penumbra from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Finally, BidaskClub lowered shares of Penumbra from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th.

A number of institutional investors and hedge funds have recently bought and sold shares of PEN. Principal Financial Group Inc. boosted its position in Penumbra by 0.9% during the first quarter. Principal Financial Group Inc. now owns 13,031 shares of the company’s stock worth $1,087,000 after acquiring an additional 121 shares during the last quarter. Teachers Advisors LLC boosted its position in Penumbra by 10.7% during the first quarter. Teachers Advisors LLC now owns 46,645 shares of the company’s stock worth $3,893,000 after acquiring an additional 4,515 shares during the last quarter. Legal & General Group Plc boosted its position in Penumbra by 43.6% during the first quarter. Legal & General Group Plc now owns 8,946 shares of the company’s stock worth $747,000 after acquiring an additional 2,717 shares during the last quarter. BlackRock Inc. boosted its position in Penumbra by 82,715.0% during the first quarter. BlackRock Inc. now owns 1,733,318 shares of the company’s stock worth $144,643,000 after acquiring an additional 1,731,225 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Penumbra by 7.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 112,603 shares of the company’s stock worth $9,397,000 after acquiring an additional 7,967 shares during the last quarter. Hedge funds and other institutional investors own 72.73% of the company’s stock.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.